Cosmo Pharmaceuticals NV (XSWX:COPN) EV-to-EBIT : 40.98 (As of May. 16, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Cosmo Pharmaceuticals NV EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cosmo Pharmaceuticals NV's Enterprise Value is CHF1,135.4 Mil. Cosmo Pharmaceuticals NV's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was CHF27.7 Mil. Therefore, Cosmo Pharmaceuticals NV's EV-to-EBIT for today is 40.98.

The historical rank and industry rank for Cosmo Pharmaceuticals NV's EV-to-EBIT or its related term are showing as below:

XSWX:COPN' s EV-to-EBIT Range Over the Past 10 Years
Min: -92.4 Med: 18.64 Max: 659.78
Current: 40.99

During the past 13 years, the highest EV-to-EBIT of Cosmo Pharmaceuticals NV was 659.78. The lowest was -92.40. And the median was 18.64.

XSWX:COPN's EV-to-EBIT is ranked worse than
81.86% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.74 vs XSWX:COPN: 40.99

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cosmo Pharmaceuticals NV's Enterprise Value for the quarter that ended in Jun. 2023 was CHF688.7 Mil. Cosmo Pharmaceuticals NV's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was CHF27.7 Mil. Cosmo Pharmaceuticals NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was 4.02%.

Cosmo Pharmaceuticals NV EV-to-EBIT Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV EV-to-EBIT Chart

Cosmo Pharmaceuticals NV Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-EBIT

Get a 7-Day Free Trial

-57.43

-71.72

604.67

30.56

28.18

Cosmo Pharmaceuticals NV Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EV-to-EBIT	Get a 7-Day Free Trial															-	30.56	-	28.18	-

Competitive Comparison of Cosmo Pharmaceuticals NV's EV-to-EBIT

For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cosmo Pharmaceuticals NV's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cosmo Pharmaceuticals NV's EV-to-EBIT falls into.

Cosmo Pharmaceuticals NV EV-to-EBIT Calculation

Cosmo Pharmaceuticals NV's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1135.369	/	27.703
	=	40.98

Cosmo Pharmaceuticals NV's current Enterprise Value is CHF1,135.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo Pharmaceuticals NV's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was CHF27.7 Mil.

Cosmo Pharmaceuticals NV (XSWX:COPN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cosmo Pharmaceuticals NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 )	=	EBIT	/	Enterprise Value (Q: Jun. 2023 )
	=	27.703	/	688.742
	=	4.02 %

Cosmo Pharmaceuticals NV's Enterprise Value for the quarter that ended in Jun. 2023 was CHF688.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo Pharmaceuticals NV's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was CHF27.7 Mil.

Cosmo Pharmaceuticals NV EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmo Pharmaceuticals NV (XSWX:COPN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (XSWX:COPN) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

CMOPF:USA COPNz:UK C43:Germany

Address

Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2

Website

https://www.cosmopharma.com

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (XSWX:COPN) Headlines

No Headlines